Loading
Immune Cells in Cancer · Journal article
International Journal of Molecular Sciences · September 3, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review examining the heterogeneous and context-dependent roles of MDSCs in obesity-associated diabetes and cardiovascular disease, integrating preclinical mechanistic insights with observational human data. The authors acknowledge a fundamental paradox: MDSCs can exert either atheroprotective and cardioprotective effects or contribute to heightened cardiovascular risk depending on cellular subset, glycemic control, and tissue localization. The review concludes that MDSC phenotypic and functional heterogeneity presents a critical clinical challenge and evaluates their potential as biomarkers and therapeutic targets, but does not resolve the conflicting evidence base.
Narrative review. Patients with obesity-associated type 2 diabetes and cardiovascular disease; mechanistic insights from preclinical models.
MDSCs undergo substantial expansion and accumulation within peripheral tissues (adipose tissue and liver) in obesity and type 2 diabetes Specific monocytic MDSC subsets demonstrate atheroprotective and cardioprotective capabilities by dampening Th1/Th17-mediated arterial wall inflammation and stabilizing atherosclerotic plaques Persistent or altered MDSC subsets correlate with heightened cardiovascular risk and adverse cerebrovascular outcomes
Persistent or altered MDSC subsets correlate with heightened cardiovascular risk and adverse cerebrovascular outcomes
Clinicians should recognize that MDSCs represent a heterogeneous cell population with context-dependent effects in cardiometabolic disease; current evidence does not support routine clinical use of MDSC-targeted interventions pending resolution of conflicting protective versus detrimental effects and clarification of subset-specific roles.
This is a narrative review synthesizing preclinical mechanisms and observational human data on MDSC biology in cardiometabolic disease, raising questions about dualistic roles rather than reporting new empirical results.
As stated by the source record.
Clinicians should recognize that MDSCs represent a heterogeneous cell population with context-dependent effects in cardiometabolic disease; current evidence does not support routine clinical use of MDSC-targeted interventions pending resolution of conflicting protective versus detrimental effects and clarification of subset-specific roles.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The dysregulation of immune homeostasis and the persistence of chronic, low-grade inflammation represent core pathophysiological drivers governing the onset and progression of metabolic and cardiovascular disorders. Myeloid-derived suppressor cells (MDSCs) comprise a highly heterogeneous population of immature myeloid cells that are rapidly mobilized from the bone marrow in response to biological stressors, such as sustained tissue injury and chronic inflammatory signaling. Historically evaluated within oncology and infectious disease frameworks, accumulating evidence highlights the pivotal, context-dependent roles of MDSCs in cardiometabolic environments. In conditions of obesity and type 2 diabetes (T2D), MDSCs undergo substantial expansion and accumulation within peripheral tissues, including adipose tissue and the liver. Functionally, MDSCs act as dynamic immunoregulators that can either buffer metabolic inflammation, via the secretion of interleukin-10 (IL-10), transforming growth factor-beta (TGF-β), and nitric oxide (NO) or, conversely, reflect and exacerbate disease progression depending on specific cellular subsets, glycemic control, and tissue localization. Within the vascular system, specific monocytic MDSC subsets demonstrate significant atheroprotective and cardioprotective capabilities by dampening Th1/Th17-mediated arterial wall inflammation, stabilizing atherosclerotic plaques, and preserving cardiac structural architecture during heart failure. However, phenotypic and functional heterogeneity poses a critical clinical challenge, as certain persistent or altered subsets correlate with heightened cardiovascular risk and adverse cerebrovascular outcomes. This review delivers a comprehensive synthesis of contemporary insights into MDSC biology at the intersection of obesity-associated diabetes and cardiovascular disease, characterizing their dualistic mechanisms, distinguishing preclinical causal mechanisms from human observational data. Moreover, we have established a comprehensive framework to reconcile the conflicting protective versus detrimental effects of MDSCs. And finally, we have also evaluated their potential clinical utility as candidate biomarkers, delineating the safety imperatives essential for translating MDSC-targeted therapeutic interventions into clinical practice.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.